NEW YORK, December 5, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS), XOMA Corporation (NASDAQ: XOMA), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and Arrowhead Research Corp. (NASDAQ: ARWR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Allergan Inc. Research Report
On December 2, 2013, Allergan Inc. (Allergan) announced the completion of sale of its obesity intervention business to Apollo Endosurgery, Inc. (Apollo Endosurgery). Allergan stated that it has received a cash payment of $75 million, subject to certain adjustments, and a $15 million minority equity interest in Apollo Endosurgery, under the terms of the agreement which was initially announced on October 29, 2013. The Company added that it may also receive up to $20 million in contingent consideration after achieving certain regulatory and sales milestones. The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Zoetis Inc. Research Report
On November 26, 2013, Zoetis Inc. (Zoetis) announced its participation in the 2013 Bank of America Merrill Lynch Animal Health Summit on December 16, 2013 at the Bank of America Conference Center in Boston, Massachusetts. Zoetis stated that its CEO, Juan Ramón Alaix, will be the keynote speaker on behalf of the Company, and is scheduled to present at 12:35 p.m. The Company added that presentation materials can be accessed through its website after the keynote speech is over. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
XOMA Corporation Research Report
On November 20, 2013, XOMA Corp. (XOMA) announced that it has been awarded U.S. patent no. 8,584,349, entitled "Flexible Manufacturing System" by the United States Patent and Trademark Office. XOMA stated that the patent relates to modular, flexible manufacturing facilities. Commenting on the patent, Pat Scannon, Founder and Chief Scientific Officer of XOMA, stated, "This is a fundamental patent for XOMA in the fast emerging flexible manufacturing field. With 5 of the top 10 selling drugs globally being biologics, the emphasis on discovering and developing new biologic drug candidates has never been higher. Fast, flexible manufacturing techniques address a key hurdle in early stage biologics development - that of creating drug supply in appropriate quantities in the clinical development process." The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Isis Pharmaceuticals, Inc. Research Report
On December 2, 2013, Isis Pharmaceuticals Inc. (Isis) announced that it has earned a $2 million milestone payment from GlaxoSmithKline (GSK) pertaining to the advancement of the ongoing Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). The Company stated that ISIS-TTRRx is an antisense drug in development with GSK for treating transthyretin amyloidosis, a genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Isis further added that if GSK chooses to exercise its option to exclusively license the ISIS-TTRRx program, Isis will be eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on ISIS-TTRRx sales. The Full Research Report on Isis Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Arrowhead Research Corp. Research Report
On November 25, 2013, Arrowhead Research Corp. (Arrowhead) announced that it has recently submitted an application for approval to initiate a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection. The Company stated that pending approval, it plans to go forward with a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Arrowhead added that the study is being conducted to establish the depth and duration of hepatitis B surface antigen (HBsAg) reduction after a single intravenous dose of ARC-520 together with entecavir in patients with chronic HBV infection. The Company further stated that an application for a Certificate for Clinical Trial was submitted to the Hong Kong Department of Health. The Full Research Report on Arrowhead Research Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner